RVL Pharmaceuticals plc to Present at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference

Rhea-AI Summary

RVL Pharmaceuticals plc (Nasdaq: RVLP) announced that CEO Brian Markison will participate in a panel and host 1x1 investor meetings at the Cantor Medical & Aesthetic Dermatology Conference in Miami, FL, on December 8, 2022, at 9:00 am ET. RVL specializes in UPNEEQ®, the first FDA-approved non-surgical treatment for acquired blepharoptosis. Investors can request meetings via corporateaccess@cantor.com.

BRIDGEWATER, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that Brian Markison, Chief Executive Officer, will participate in a panel presentation and host 1x1 investor meetings at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference in Miami, FL, as follows:

Date:	Thursday, December 8, 2022
Time:	9:00am ET

1x1 investor meetings can be requested via corporateaccess@cantor.com.

About RVL Pharmaceuticals plc

RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization of UPNEEQ^® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.

Investor and Media Relations for RVL Pharmaceuticals plc

Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

IMPORTANT SAFETY INFORMATION

INDICATION

UPNEEQ^® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.

WARNINGS AND PRECAUTIONS

• Ptosis may be associated with neurologic or orbital diseases such as stroke and/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses. Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs.
• Alpha-adrenergic agonists as a class may impact blood pressure. Advise UPNEEQ patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.
• Use UPNEEQ with caution in patients with cerebral or coronary insufficiency or Sjögren’s syndrome. Advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop.
• UPNEEQ may increase the risk of angle closure glaucoma in patients with untreated narrow-angle glaucoma. Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle glaucoma develop.
• Patients should not touch the tip of the single patient-use container to their eye or to any surface, in order to avoid eye injury or contamination of the solution.
  

ADVERSE REACTIONS

Adverse reactions that occurred in 1-5% of subjects treated with UPNEEQ were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation and headache.

DRUG INTERACTIONS

• Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as betablockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy.
• Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.

FAQ

What event will RVLP's CEO participate in on December 8, 2022?

CEO Brian Markison will participate in the Cantor Medical & Aesthetic Dermatology Conference in Miami, FL.

What time is RVLP's presentation at the conference?

The presentation is scheduled for 9:00 am ET on December 8, 2022.

How can investors meet with RVLP's CEO during the conference?

Investors can request 1x1 meetings via corporateaccess@cantor.com.

What product does RVL Pharmaceuticals focus on?

RVL Pharmaceuticals specializes in UPNEEQ®, a treatment for acquired blepharoptosis.

What is UPNEEQ® and its significance?

UPNEEQ® is the first FDA-approved non-surgical option for treating acquired blepharoptosis in adults.